Clinical Trials

The physicians and staff at Advanced Cancer Therapies and Wichita Urology Group devote a portion of their time to the future by participating in clinical research to discover improved treatment options and more beneficial therapies for urological cancers. This involvement gives you access to advanced procedures and treatment options that might not otherwise be available. If you are interested in participating in a clinical trial, one of our urologists can determine if you qualify. Once the clinical trial process begins, you will be closely monitored and informed of all benefits and potential risks associated with the trial. Patients can opt out of the trial at any time.

Please feel free to talk with your physician if you are interested in learning more about one of our trials.

When You Join a Research Trial

  • You help bring new methods of preventing, diagnosing and treating diseases, including cancer.
  • Have an opportunity to learn more about your cancer with more individualized care.
  • Receive tests and study medication at no cost.

Currently Enrolling

This accordion is meant to set Elementor Accordion closed by default.

Custom CSS

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B). For more information, please visit: clinicaltrials.gov

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is naïve to BCG treatment (Cohort B). The primary hypothesis for Cohort A is that the combination of pembrolizumab plus BCG has a superior complete response rate (CRR) as assessed by central pathology review compared to BCG in participants with carcinoma in situ (CIS). The primary hypothesis for Cohort B is that the combination of pembrolizumab plus BCG (either reduced maintenance or full maintenance) has a superior Event Free Survival (EFS) compared to BCG.

For more information please visit clinicaltrials.gov

Urine analysis using OpsisDx

Detecting cancers earlier through elective plasma-based CancerSEEK Testing

Semen sample collection and processing for use in the development of prostate cancer diagnostic tests

This is a prospective, multi-center, observational study with a collection of biospecimens and clinical data from approximately 10,000 participants from up to 40 clinical network sites and locations in the United States. The objective of this study is to collect blood samples, tissue samples, and associated clinical data from participants with a variety of solid tumor and hematologic cancers and non-cancer participants for testing and the development of a screening test for early cancer detection.

For more information, please visit: clinicaltrials.gov

The purpose of this clinical study is to collect data to substantiate the use of the VITROS Total PSA III test as an aid in Detection of prostate cancer.

Early feasibility study of neuromodulation in patients with IBD.

For more information, please visit: clinicaltrials.gov

The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC

For more information, please visit: clinicaltrials.gov

The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body. When a patient is enrolled to the study, his/her physician would have already made the decision to treat patient with darolutamide per local standard practice.

For more information please visit clinicaltrials.gov

This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.

For more information, please visit: clinicaltrials.gov

A Phase 1/2a, open-label, multicenter study of intramuscular (i.m.) PRL-02 depot in participants with advanced prostate cancer.

For more information, please visit: clinicaltrials.gov

Ongoing Studies - Not Enrolling

This accordion is meant to set Elementor Accordion closed by default.

Custom CSS

  • NCT05059236
  • The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by progression-free survival. The researchers want to learn how long it takes for the cancer to get worse (also known as “progression-free survival”) by either increasing symptoms, new metastases, PSA rise or death. All participants will be on treatment and take darolutamide with ADT until their cancer spreads, they have a medical problem, or they leave the study. The results will then be compared with patients’ results from another study who received ADT alone (CHAARTED). This study will also assess safety by gathering adverse event information throughout the duration of the study. An adverse event is any medical problem, related or not to study treatment that a participant has during a study. The study drug, darolutamide, is already available for doctors to prescribe to patients with prostate cancer that has not yet spread to other parts of the body. It works by blocking a protein called a receptor from attaching to a hormone called androgen that is found in men. This protein can also be found in prostate cancer cells. ADT is a treatment that doctors are currently able to prescribe to patients with mHSPC. ADT is used to lower the amount of the androgen hormone.
  • Link: https://clinicaltrials.gov/ct2/show/NCT05059236?term=ARASEC&cond=Prostate+Cancer&draw=2&rank=1

Main Study: The purpose of main study is to assess if the combination of apalutamide and androgen deprivation therapy (ADT) in participants with high-risk localized prostate cancer improves the biochemical recurrence (BCR) free rate.

Sub-study: The purpose of the sub-study is to assess if the co administration of apalutamide and relugolix is able to maintain castrate levels of testosterone.

For more information please visit clinicaltrials.gov

Learn More About Clinical Trials

Speak with your provider or call our research office at (316) 636-6141.